Equities research analysts expect Recro Pharma Inc (NASDAQ:REPH) to report $16.77 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Recro Pharma’s earnings. The lowest sales estimate is $15.32 million and the highest is $18.00 million. Recro Pharma posted sales of $17.11 million during the same quarter last year, which suggests a negative year-over-year growth rate of 2%. The business is scheduled to issue its next earnings results on Thursday, November 8th.
According to Zacks, analysts expect that Recro Pharma will report full-year sales of $72.73 million for the current financial year, with estimates ranging from $71.00 million to $73.43 million. For the next year, analysts expect that the company will report sales of $77.80 million, with estimates ranging from $71.00 million to $88.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Recro Pharma.
Recro Pharma (NASDAQ:REPH) last posted its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.34) by $0.72. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%. The firm had revenue of $21.74 million during the quarter, compared to analysts’ expectations of $16.81 million.
Shares of NASDAQ:REPH traded up $0.01 on Wednesday, hitting $7.20. The company had a trading volume of 204,643 shares, compared to its average volume of 265,424. Recro Pharma has a 1 year low of $4.78 and a 1 year high of $13.05. The company has a current ratio of 1.59, a quick ratio of 1.42 and a debt-to-equity ratio of 2.22. The stock has a market cap of $147.30 million, a price-to-earnings ratio of -3.62 and a beta of -0.82.
Several institutional investors have recently modified their holdings of REPH. Newtyn Management LLC bought a new position in shares of Recro Pharma in the 2nd quarter worth about $4,456,000. Lyon Street Capital LLC increased its stake in shares of Recro Pharma by 182.6% in the 1st quarter. Lyon Street Capital LLC now owns 1,027,271 shares of the specialty pharmaceutical company’s stock worth $11,310,000 after acquiring an additional 663,776 shares in the last quarter. Engine Capital Management LP increased its stake in shares of Recro Pharma by 472.3% in the 2nd quarter. Engine Capital Management LP now owns 391,307 shares of the specialty pharmaceutical company’s stock worth $1,964,000 after acquiring an additional 322,937 shares in the last quarter. Millennium Management LLC bought a new position in shares of Recro Pharma in the 1st quarter worth about $3,060,000. Finally, Sanders Morris Harris LLC bought a new position in shares of Recro Pharma in the 2nd quarter worth about $1,391,000. Institutional investors own 55.86% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Further Reading: Do Tariffs Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.